Source-grounded facts extracted from Korro Bio, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Korro Bio, Inc. terminated Sublease Agreement with Saliogen Therapeutics, Inc. valued at No payments or costs (effective 2024-01-31).
“Also on August 11, 2023, the Company entered into a Sublease Termination Agreement with Saliogen Therapeutics, Inc. (“Subtenant”), pursuant to which the parties agreed to terminate that certain Sublease Agreement, by and between the Company and Subtenant, dated as of July 8, 2022 (the “Sublease”), on January 31, 2024 (the “Sublease Termination Agreement”).”
Korro Bio, Inc. terminated Indenture of Lease (Master Lease) with LS 75 Hayden LLC valued at No payments or costs (effective 2024-01-31).
“On August 11, 2023, Frequency Therapeutics, Inc. (the “Company”) entered into a Termination Agreement with LS 75 Hayden LLC (“Landlord”) for certain premises located at 75 Hayden Avenue, Lexington, Massachusetts (the “Lease Termination Agreement”). The Lease Termination Agreement provides that the Indenture of Lease (the “Master Lease”), dated as of January 7, 2020, by and between the Company and the Landlord will terminate on January 31, 2024.”
Korro Bio, Inc. reported the six months ended June 30, 2023 results: net income $30.3 million.
“Net loss was $30.3 million for the six months ended June 30, 2023”
Korro Bio, Inc. reported the three months ended June 30, 2023 results: net income $10.8 million.
“Net loss was $10.8 million for the three months ended June 30, 2023”
Christopher Loose resigned as Chief Scientific Officer at Korro Bio, Inc..
“On July 28, 2023, Christopher Loose, Ph.D., notified Frequency Therapeutics, Inc. (the “Company”) that he would be resigning from his position as Chief Scientific Officer of the Company, effective July 28, 2023”
Korro Bio, Inc. entered into Subscription Agreements with certain accredited investors valued at approximately $117 million (effective 2023-07-14).
“On July 14, 2023, Korro Bio entered into subscription agreements with certain accredited investors for the Concurrent Financing with expected gross proceeds to Korro Bio of approximately $117 million.”
Korro Bio, Inc. entered into Agreement and Plan of Merger with Frequency Therapeutics, Inc., Frequency Merger Sub, Inc. valued at approximately $325.6 million (effective 2023-07-14).
“On July 14, 2023, Frequency Therapeutics, Inc. (“ Frequency ” or the “ Company ”), Frequency Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“ Merger Sub ”), and Korro Bio, Inc., a Delaware corporation (“ Korro Bio ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”)”
Korro Bio, Inc. announced a restructuring with charges of approximately $1.16 million (approximately 55% of its workforce).
“On May 31, 2023, Frequency Therapeutics, Inc. (the “Company”) announced a reduction in force (the “Reduction”) of approximately 55% of its workforce. The purpose of the Reduction, which was approved by the Board of Directors (the “Board”) of the Company on May 31, 2023, is to better align the Company’s workforce with the changing needs of its business. The Reduction will be completed by June 9, 2023. The total costs related to the Reduction are estimated to be approximately $1.16 million in future cash outlays primarily related to severance costs and related expenses.”
Korro Bio, Inc. reported the quarter ended March 31, 2023 results: net income Net loss was $19.5 million.
“On May 12, 2023, Frequency Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2023”
Joel S. Marcus resigned as Director at Korro Bio, Inc..
“On May 5, 2023, Joel S. Marcus notified Frequency Therapeutics, Inc. (the “Company”) of his resignation from the Company’s Board of Directors (the “Board”) and all committees of the Board on which he served, which was immediately effective.”
Korro Bio, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“March 28, 2023, Frequency Therapeutics, Inc. (the “Company”) received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock, par value $ 0.001 per share (the “Common Stock”), had closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). The deficiency letter has no immediate effect on the lis”
Carl LeBel was terminated as Chief Development Officer at Korro Bio, Inc..
“On February 13, 2023, Carl LeBel, Ph.D., Chief Development Officer of Frequency Therapeutics, Inc. (the “Company”), was notified by the Company that his employment would be terminated on March 31, 2023 (the “Separation Date”) as part of a reduction in force that was previously announced by the Company.”
Korro Bio, Inc. reported Fourth Quarter and Full Year 2022 results: net income Net loss was $17.4 million for the three months ended December 31, 2022, as compared to $21.5 million for the comparable.
“Net loss was $17.4 million for the three months ended December 31, 2022, as compared to $21.5 million for the comparable period of 2021. Net loss was $81.6 million for the full year ended December 31, 2022, as compared to $84.7 million for the comparable period of 2021.”
Korro Bio, Inc. announced a restructuring with charges of approximately $4 million (approximately 55% of its workforce).
“Also on February 13, 2023, the Company announced a reduction in force (the “Reduction”) of approximately 55% of its workforce. The purpose of the Reduction, which was approved by the Board of Directors of the Company on February 11, 2023, is to better align the Company’s workforce with the needs of its business and focus more of its capital resources on its pre-clinical program for remyelination in Multiple Sclerosis (the “MS Program”). These changes will preserve capital, ensuring that the Company is appropriately resourced to complete a first clinical trial of its MS Program. The Reduction will take place in phases and be completed by April 30, 2023. The total costs related to the Reduction are estimated to be approximately $4 million in future cash outlays primarily related to severance costs and related expenses.”
Carl P. LeBel departed as Chief Development Officer at Korro Bio, Inc..
“As part of the Reduction, Carl P. LeBel, Ph.D. will be stepping down as the Company’s Chief Development Officer, effective March 31, 2023.”
Christopher Loose was appointed as Interim Chief Executive Officer at Korro Bio, Inc..
“On February 11, 2023, the Company’s Board of Directors appointed Christopher Loose, Ph.D., as Interim Chief Executive Officer while David Lucchino, the Company’s President and Chief Executive Officer, is on a temporary medical leave of absence after being hospitalized with bacterial meningitis.”
Korro Bio, Inc. reported financial results for the third quarter ended September 30, 2022.
“Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced business updates and financial results for the third quarter ended September 30, 2022.”
Richard M. Mitrano was appointed as principal financial officer and principal accounting officer at Korro Bio, Inc..
“On April 5, 2022, the Board appointed Richard M. Mitrano, the Company’s Vice President of Finance and Operations, as the Company’s principal financial officer and principal accounting officer”
Peter P. Pfreundschuh departed as Chief Financial Officer at Korro Bio, Inc..
“On April 5, 2022, the Board appointed Richard M. Mitrano, the Company’s Vice President of Finance and Operations, as the Company’s principal financial officer and principal accounting officer, succeeding Peter P. Pfreundschuh, the Company’s former Chief Financial Officer.”
Peter P. Pfreundschuh departed as Chief Financial Officer at Korro Bio, Inc..
“On March 25, 2022, Peter P. Pfreundschuh notified Frequency Therapeutics, Inc. (the “Company”) that he was stepping down as Chief Financial Officer of the Company, effective March 31, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.